SCA
PFE icon

Sippican Capital Advisors’s Pfizer PFE Stock Holding History

Sippican Capital Advisors’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.46M Buy
102,177
+2,945
+3% +$77K 1.5% 26
2026
Q1 		$2.79M Sell
99,232
-1,635
-2% -$43.5K 1.91% 11
2025
Q4 		$2.51M Buy
100,867
+1,760
+2% +$44.4K 1.61% 18
2025
Q3 		$2.53M Buy
99,107
+6,195
+7% +$153K 1.67% 16
2025
Q2 		$2.25M Buy
92,912
+25,285
+37% +$590K 1.64% 20
2025
Q1 		$1.71M Buy
67,627
+26,230
+63% +$686K 1.29% 27
2024
Q4 		$1.1M Sell
41,397
-46,929
-53% -$1.27M 0.8% 49
2024
Q3 		$2.56M Buy
88,326
+27
+0% +$788 1.78% 17
2024
Q2 		$2.47M Buy
88,299
+5,537
+7% +$152K 1.96% 12
2024
Q1 		$2.3M Buy
82,762
+14,618
+21% +$406K 1.79% 14
2023
Q4 		$1.96M Buy
68,144
+18,657
+38% +$564K 1.54% 19
2023
Q3 		$1.64M Buy
49,487
+4,873
+11% +$172K 1.48% 26
2023
Q2 		$1.64M Sell
44,614
-280
-0.6% -$10.9K 1.51% 25
2023
Q1 		$1.83M Buy
44,894
+587
+1% +$25.4K 1.75% 15
2022
Q4 		$2.27M Sell
44,307
-255
-0.6% -$12.2K 2.17% 7
2022
Q3 		$1.95M Sell
44,562
-75
-0.2% -$3.64K 2.03% 9
2022
Q2 		$2.34M Sell
44,637
-249
-0.6% -$12.7K 2.32% 5
2022
Q1 		$2.32M Sell
44,886
-878
-2% -$45.6K 1.93% 8
2021
Q4 		$2.7M Sell
45,764
-2,410
-5% -$119K 2.3% 5
2021
Q3 		$2.07M Sell
48,174
-1,535
-3% -$68K 1.8% 14
2021
Q2 		$1.95M Sell
49,709
-757
-2% -$29.4K 1.69% 17
2021
Q1 		$1.83M Buy
50,466
+6,761
+15% +$240K 1.69% 15
2020
Q4 		$1.61M Sell
43,705
-4,107
-9% -$151K 1.75% 14
2020
Q3 		$1.67M Buy
47,812
+1,174
+3% +$41.2K 2.07% 11
2020
Q2 		$1.45M Sell
46,638
-1,833
-4% -$62.3K 1.95% 12
2020
Q1 		$1.5M Buy
48,471
+628
+1% +$21.4K 2.44% 8
2019
Q4 		$1.78M Sell
47,843
-2
-0% -$71 1.98% 13
2019
Q3 		$1.63M Sell
47,845
-237
-0.5% -$8.62K 1.97% 13
2019
Q2 		$1.98M Sell
48,082
-1,239
-3% -$49.2K 2.33% 7
2019
Q1 		$1.99M Sell
49,321
-604
-1% -$24.2K 2.36% 6
2018
Q4 		$2.07M Buy
49,925
+843
+2% +$35K 2.79% 5
2018
Q3 		$2.04M Sell
49,082
-4,486
-8% -$173K 2.36% 7
2018
Q2 		$1.84M Buy
53,568
+2,845
+6% +$97.2K 1.84% 16
2018
Q1 		$1.71M Buy
50,723
+106
+0.2% +$3.64K 1.77% 14
2017
Q4 		$1.74M Buy
50,617
+158
+0.3% +$5.39K 1.7% 17
2017
Q3 		$1.71M Buy
50,459
+8,890
+21% +$286K 1.75% 18
2017
Q2 		$1.32M Buy
41,569
+5,754
+16% +$181K 1.44% 23
2017
Q1 		$1.16M Buy
35,815
+4,158
+13% +$131K 1.23% 34
2016
Q4 		$976K Buy
31,657
+11,058
+54% +$338K 1.02% 35
2016
Q3 		$662K Buy
20,599
+2,268
+12% +$75.8K 0.76% 51
2016
Q2 		$612K Buy
18,331
+3,252
+22% +$104K 0.73% 51
2016
Q1 		$424K Buy
15,079
+5,190
+52% +$148K 0.54% 61
2015
Q4 		$303K Buy
9,889
+132
+1% +$4.15K 0.38% 77
2015
Q3 		$291K Sell
9,757
-632
-6% -$20.3K 0.37% 80
2015
Q2 		$331K Buy
10,389
+131
+1% +$4.27K 0.33% 82
2015
Q1 		$339K Buy
10,258
+607
+6% +$19.3K 0.35% 85
2014
Q4 		$285K Hold
9,651
– – 0.28% 89
2014
Q3 		$271K Buy
+9,651
New +$271K 0.28% 96

Other funds holding PFE

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
CWP
Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
WG
Welch Group Birmingham, Alabama $2.93B AUM 27.62% 1-Year Est. Return

Sippican Capital Advisors's PFE Position: Q2 2026 in Review

Sippican Capital Advisors increased its Pfizer (PFE) stake by 3% in Q2 2026, buying an estimated $77K and bringing the position to 102,177 shares worth $2.46M. The position accounts for 1.5% of the portfolio, ranked #26.

Sippican Capital Advisors first reported a position in PFE in Q3 2014 and has held it in 48 quarters since. The position peaked at $2.79M in Q1 2026. 900 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Sippican Capital Advisors held 102,177 shares of Pfizer worth $2.46M as of Q2 2026.
  • Sippican Capital Advisors bought 2,945 Pfizer shares in Q2 2026, an estimated $77K.
  • Pfizer made up 1.5% of Sippican Capital Advisors's portfolio in Q2 2026, its #26 holding.
  • Sippican Capital Advisors first reported a position in Pfizer in Q3 2014 and has held it in 48 quarters since.
  • Sippican Capital Advisors's Pfizer position peaked at $2.79M in Q1 2026.
  • 900 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Sippican Capital Advisors's 13F filing for Q2 2026, filed 22 Jul 2026.